Evidence map›Paper›PMID 39967210›Full record

ArticleJACC. CardioOncology2025

Effects of Systemic Anticancer Treatment on Cardiorespiratory Fitness: A Systematic Review and Meta-Analysis.

Sara H Johansen, Torbjørn Wisløff, Elisabeth Edvardsen, Sofie T Kollerud, Johanne S S Jensen, Ginika Agwu, Konstantina Matsoukas, Jessica M Scott, Tormod S Nilsen

Abstract read
In one paragraph

Article in JACC. CardioOncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. The intersection of colorectal cancer and cardiovascular disease: shared mechanisms and clinical implications.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Exercise Prescription in Cardio-Oncology.Journal of clinical medicine · 2025
    Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sara H JohansenDepartment of Physical Performance, The Norwegian School of Sport Sciences, Oslo, Norway. Electronic address: sarahj@nih.no.
Torbjørn WisløffHealth Services Research Unit, Akershus University Hospital, Lørenskog, Norway.
Elisabeth EdvardsenDepartment of Pulmonary Medicine, Oslo University Hospital, Oslo, Norway.
Sofie T KollerudDepartment of Physical Performance, The Norwegian School of Sport Sciences, Oslo, Norway.
Johanne S S JensenDepartment of Physical Performance, The Norwegian School of Sport Sciences, Oslo, Norway.
Ginika AgwuMemorial Sloan Kettering Cancer Center, New York, New York, USA.
Konstantina MatsoukasMemorial Sloan Kettering Cancer Center, New York, New York, USA.
Jessica M ScottMemorial Sloan Kettering Cancer Center, New York, New York, USA.
Tormod S NilsenDepartment of Physical Performance, The Norwegian School of Sport Sciences, Oslo, Norway.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Michael Jason de la Cruz · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

backgroundPoor cardiorespiratory fitness (CRF) is associated with a higher symptom burden and an increased prevalence of long-term treatment-related cardiovascular disease risk factors in cancer survivors. However, the magnitude of systemic therapy-related CRF impairment remains unclear.

objectivesThe aim of this study was to evaluate the effects of systemic anticancer treatment on CRF and identify physiological determinants underpinning CRF impairment.

methodsA systematic literature search was performed in PubMed, Embase, CINAHL, SPORTDiscus, and the Cochrane Library. The primary endpoint was the change in CRF, measured by peak oxygen consumption (Vo

resultsA total of 44 studies were included, comprising 27 prospective trials (61%; n = 1,234 cancer survivors, median age 52.4 years) and 17 cross-sectional studies (39%; n = 1,372 cancer survivors, median age 54.0 years; n = 1,923 noncancer control subjects, median age 56.0 years). Systemic anticancer treatment was associated with a significant decrease in Vo

conclusionsSystemic anticancer treatment leads to substantial and sustained impairments in CRF.

Indexed as

alkylating therapyanthracyclinecancercardiorespiratory fitnesspeak oxygen consumptionphysiological determinantssurvivorshipsystemic anticancer treatmenttreatmentV(O2) and exercise

Identifiers

PMID39967210
PMCPMC11866419

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.